Department of Pharmaceutical Products
Development of Active Pharmaceutical Ingredient (API) manufacturing technology
– Development of technologies for the production of active substances on a mini-synthetic and semi-technical scale
– Scaling up with validation of ongoing processes
– Organic synthesis of GMP and non-GMP
– Conducting various chemical processes (synthesis, catalytic reduction, oxidation, condensation, cyclisation) and physicochemical processes (jet micronisation, crystallisation, large-scale liquid chromatography, fractional distillation) in qualified equipment and technological installations.
API for commercialisation
| Substance | Field of activity |
| 1. Bimatoprost | Analog prostaglandyny F2α stosowany w leczeniu jaskry i wysokiego ciśnienia w gałce ocznej |
| 2. Bosentan | A dual endothelin receptor antagonist (ERA) with affinity for ETA and ETB receptors. Reduces pulmonary and systemic vascular resistance; hypertension. |
| 3. Brinzolamide | Glaucoma, carbonic anhydrase inhibitor |
| 4. Exemestane | Irreversible steroidal aromatase inhibitor, breast cancer |
| 5. Fingolimod | Multiple sclerosis |
| 6. Lapatinib | Inhibitor of EGFR (ErbB1) and ErbB2 (HER2) tyrosine kinase; lung and breast cancer, breast cancer with overexpression of the HER2 (ErbB2) receptor |
| 7. Nepafenac | Precursor of non-steroidal anti-inflammatory drugs; cataracts: prevention and treatment of pain and inflammation after surgery, reduction of the risk of postoperative macular oedema |
| 8. Olopatadine | Antihistamine and anti-inflammatory drug |
| 9. Oseltamivir | Antiviral medicine indicated for the treatment of influenza |
| 10. Pemetrexed | Folic acid antagonist, treatment of non-small cell lung cancer |
Analytical patterns
|
|
|
